Rearmed Bifunctional Chelating Ligand for 225 Ac/ 155 Tb Precision-Guided Theranostic Radiopharmaceuticals─H 4 noneunpaX
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c01151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Luke Wharton und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Ca…. Hauptthemen laut MEDLINE: Chelating Agents, Radiopharmaceuticals. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, National Research Council Canada, Natural Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
Superior bifunctional chelating ligands, which can sequester both α-emitting radionuclides (225Ac, 213Bi) and their diagnostic companions (155Tb, 111In), remain a formidable challenge to translating targeted alpha therapy, with complementary diagnostic imaging, to the clinic. H4noneupaX, a chelating ligand with an unusual diametrically opposed arrangement of pendant donor groups, has been developed to this end. H4noneunpaX preferentially complexes Ln3+ and An3+ ions, forming thermodynamically stable (pLa = 17.8, pLu = 21.3) and kinetically inert complexes─single isomeric species by nuclear magnetic resonance and density functional theory. Metal binding versatility demonstrated in radiolabeling [111In]In3+, [155Tb]Tb3+, [177Lu]Lu3+, and [225Ac]Ac3+ achieved high molar activities under mild conditions. Efficient, scalable synthesis enabled in vivo evaluation of bifunctional H4noneunpaX conjugated to two octreotate peptides targeting neuroendocrine tumors. Single photon emission computed tomography/CT and biodistribution studies of 155Tb-radiotracers in AR42J tumor-bearing mice showed excellent image contrast, good tumor uptake, and high in vivo stability. H4noneunpaX shows significant potential for theranostic applications involving 225Ac/155Tb or 177Lu/155Tb.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada.
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada.
- Department of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada.
- Molecular Oncology Group, British Columbia Cancer Research Centre (BCCRC), Vancouver, British Columbia V5Z 1L3, Canada.
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada.
- Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada.
ORCID-Profile: Luke Wharton, Hua Yang, María de Guadalupe Jaraquemada-Peláez, Paul Schaffer, François Bénard, Chris Orvig
Förderung
- Canadian Institutes of Health Research
- National Research Council Canada
- Natural Sciences and Engineering Research Council of Canada
Zitieren
APA
Wharton, L., Yang, H., Jaraquemada-Peláez, M. G., Merkens, H., Engudar, G., Ingham, A., Koniar, H., Radchenko, V., Kunz, P., Schaffer, P., Bénard, F., & Orvig, C. (2023). Rearmed Bifunctional Chelating Ligand for 225 Ac/ 155 Tb Precision-Guided Theranostic Radiopharmaceuticals─H 4 noneunpaX. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01151
Vancouver
Wharton L, Yang H, Jaraquemada-Peláez MG, Merkens H, Engudar G, Ingham A, et al. Rearmed Bifunctional Chelating Ligand for 225 Ac/ 155 Tb Precision-Guided Theranostic Radiopharmaceuticals─H 4 noneunpaX. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01151
BibTeX
@article{Wharton2023,
author = {Wharton, Luke and Yang, Hua and Jaraquemada-Peláez, María de Guadalupe and Merkens, Helen and Engudar, Gokce and Ingham, Aidan and Koniar, Helena and Radchenko, Valery and Kunz, Peter and Schaffer, Paul and Bénard, François and Orvig, Chris},
title = {Rearmed Bifunctional Chelating Ligand for 225 Ac/ 155 Tb Precision-Guided Theranostic Radiopharmaceuticals─H 4 noneunpaX},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c01151}
}
EUVIMED